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Introduction
The WNT signaling pathway has important functions in skeletal metabolism. Low-bone-mass phenotypes 
(e.g., osteoporosis-pseudoglioma syndrome [OPPG], OMIM 259770) observed in patients with loss-of-
function mutations in a coreceptor for WNT, LDL receptor–related protein 5 (LRP5) (1–3), and high-bone-
mass (HBM) phenotypes (e.g., endosteal hyperosteosis, OMIM 144750) observed in patients with gain-
of-function mutations in LRP5 (4–7) both highlight the prominent role that WNT/LRP5 signaling plays 
in the skeleton. A particularly attractive attribute of  the WNT pathway is its effects on anabolic action in 
bone; consequently, harnessing this pathway to improve skeletal properties in patients with low bone mass 
represents a major area of  investigation for the pharmaceuticals development field.
The anabolic nature of WNT action in bone has been further highlighted by studies focused on the bone 
overgrowth phenotype among patients with loss-of-function mutations in the SOST gene (sclerosteosis, OMIM 
269500), whose protein product, sclerostin, is a potent negative regulator of LRP5 signaling. Sclerostin inhibits 
LRP5 by directly binding the first β-propeller of LRP5, which disrupts interaction with the WNT1 class of  
ligands (8). Genetic disruption (9, 10) or transgenic overexpression (11, 12) of Sost in mice results in increased 
The WNT pathway has become an attractive target for skeletal therapies. High-bone-
mass phenotypes in patients with loss-of-function mutations in the LRP5/6 inhibitor Sost 
(sclerosteosis), or in its downstream enhancer region (van Buchem disease), highlight the utility 
of targeting Sost/sclerostin to improve bone properties. Sclerostin-neutralizing antibody is 
highly osteoanabolic in animal models and in human clinical trials, but antibody-based inhibition 
of another potent LRP5/6 antagonist, Dkk1, is largely inefficacious for building bone in the 
unperturbed adult skeleton. Here, we show that conditional deletion of Dkk1 from bone also has 
negligible effects on bone mass. Dkk1 inhibition increases Sost expression, suggesting a potential 
compensatory mechanism that might explain why Dkk1 suppression lacks anabolic action. To test 
this concept, we deleted Sost from osteocytes in, or administered sclerostin neutralizing antibody 
to, mice with a Dkk1-deficient skeleton. A robust anabolic response to Dkk1 deletion was manifest 
only when Sost/sclerostin was impaired. Whole-body DXA scans, μCT measurements of the femur 
and spine, histomorphometric measures of femoral bone formation rates, and biomechanical 
properties of whole bones confirmed the anabolic potential of Dkk1 inhibition in the absence of 
sclerostin. Further, combined administration of sclerostin and Dkk1 antibody in WT mice produced a 
synergistic effect on bone gain that greatly exceeded individual or additive effects of the therapies, 
confirming the therapeutic potential of inhibiting multiple WNT antagonists for skeletal health. In 
conclusion, the osteoanabolic effects of Dkk1 inhibition can be realized if sclerostin upregulation is 
prevented. Anabolic therapies for patients with low bone mass might benefit from a strategy that 
accounts for the compensatory milieu of WNT inhibitors in bone tissue.
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or decreased bone mass, respectively, which is largely driven by changes in bone formation rate. Further, scle-
rostin-neutralizing antibodies have dramatic and consistent bone-building effects in mice (13–15), rats (16–18), 
monkeys (19, 20), and humans (21, 22), leading to significant improvement in bone mass, strength, and frac-
ture susceptibility. These experiments and clinical trials attest to the therapeutic value of targeting sclerostin for 
improving skeletal properties.
Targeting other secreted inhibitors of  WNT signaling that normally disrupt the WNT-LRP5 interaction 
has appeared less promising for general treatment of  low bone mass. For example, the secreted LRP5/6 
antagonist Dkk1 is a potent inhibitor of  WNT signaling in cultured bone cells (23–25), binding directly to 
the first and third β-propellers of  LRP5/6 and disrupting interaction with WNT1- and WNT3-class ligands 
(26). Homozygous inactivation of  Dkk1 in mice is perinatal lethal, but Dkk1 haploinsufficiency (Dkk1+/–) 
(27) and/or hypomorphic mutation (e.g., doubleridge) (28) results in increased bone mass (29). However, 
pharmacologic blockade of  Dkk1 in rats and mice via neutralizing antibody is only mildly efficacious in 
young animals and is largely ineffective at improving bone mass in adult animals (30). In light of  the strong 
anabolic effects of  sclerostin neutralization, this is a puzzling finding given that Dkk1 is such a potent 
inhibitor of  the WNT–LRP5/6 interaction; at equimolar concentration Dkk1 outcompetes sclerostin for 
binding to LRP5 and can even displace pre-bound sclerostin from LRP5 receptors (31). Why, then, is Dkk1 
neutralization not more anabolic for bone?
We sought to investigate whether we could unlock fuller anabolic potential of  Dkk1 neutralization 
by trying first to better understand the auxiliary molecular events caused by Dkk1 inhibition that might 
negate its otherwise osteoanabolic effects. Data from human patients with sclerosteosis (32) and from mice 
treated with sclerostin antibody (33, 34) indicate that sclerostin deficiency results in an increase in Dkk1 
protein levels. We investigated whether the opposite compensatory mechanism exists (i.e., Dkk1 deficiency 
modulates sclerostin levels) and whether this could account for the lack of  efficacy of  Dkk1 inhibition. 
Using global and bone-selective Sost- and Dkk1-deficient mouse models, in conjunction with neutralizing 
antibodies to both proteins, the functional studies performed strongly suggest that Dkk1 neutralization is 
potently anabolic to bone tissue if  the compensatory upregulation of  sclerostin is neutralized.
Results
Mice with bone-selective deletion of  Dkk1 or WT mice treated with Dkk1-neutralizing antibody exhibit a mild bone 
phenotype. The skeletal consequences of  Sost genetic disturbances have been widely studied in mice (9, 
10, 13) and humans (35–37), but less is known about the effects of  Dkk1 loss — another potent inhibitor 
of  LRP5/6. To understand the magnitude of  the potential HBM phenotype generated by Dkk1 deletion 
in bone, while avoiding the lethal phenotype observed in global Dkk1-knockout mice (27), we bred mice 
harboring Dkk1 floxed loss-of-function alleles to the 10kbDmp1-Cre driver strain and quantified the pheno-
type radiographically. Presence of  the 10kbDmp1-Cre allele reduced Dkk1 expression by more than 80% in 
cortical bone lysates from Dkk1fl/fl mice (Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.98673DS1). Serial dual-energy x-ray absorptiome-
try (DXA) revealed a slight but significant increase in whole-body bone mineral content (BMC) among 
Cre-positive females (12% increase, P < 0.05) but not males compared with their respective Cre-negative 
Dkk1fl/fl littermates (Figure 1, A and B). Cancellous bone volume fraction at 16 weeks of  age was 6% greater 
(P < 0.05) among Cre-positive compared with Cre-negative females, but Cre-positive males did not exhibit 
a significant difference from Cre-negative male controls (Figure 1, C and D). Given previous findings of  
altered matrix composition in LRP5 and Sost mutant mice (38, 39), we also examined bone chemical prop-
erties in the conditional Dkk1 mutant mice using Fourier transform infrared imaging (FTIRI). No changes 
in matrix properties were found when Dkk1 was deleted from bone (Supplemental Figure 2)
To assess whether the surprising absence of  a robust HBM phenotype in mice with late-stage bone cell 
deletion (i.e., in Dmp1-expressing cells) of  Dkk1 was perhaps the result of  our failure to target the appro-
priate cell type (e.g., cells earlier in the lineage), we next inhibited Dkk1 more broadly by administering a 
Dkk1-neutralizing antibody to 10-week-old WT mice. Six weeks of  treatment with Dkk1 antibody (25 mg/
kg s.c., twice a week) did not significantly change DXA-derived whole-body BMC when compared with 
vehicle treatment, in either males or females, but a small but significant increase (11%, P < 0.05) in BMC as 
measured by peripheral quantitative CT (pQCT) at the proximal tibia was detected among antibody-treated 
females (Figure 1, E and F). In summary, neither bone-selective deletion of  the Dkk1 gene nor systemic 
inhibition of  extracellular Dkk1 protein increased bone mass consistently or to the extent seen in other 
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WNT pathway mutants (e.g., LRP5 HBM models, Sost models, LRP4 models) (9, 40, 41) and/or pharma-
cologic inhibition models (e.g., sclerostin neutralization) (13, 16).
Dkk1 levels and/or bioavailability regulate Sost — a potential override mechanism of  Dkk1-mediated control 
of  bone metabolism. Previous reports in mice (33, 42) and humans (32) indicate that Dkk1 expression is 
modulated by perturbations in Sost/sclerostin expression. We sought to address the reciprocal situa-
tion, to understand whether Sost expression is modulated by Dkk1 perturbation. In particular, we asked 
whether Sost expression increases in response to Dkk1 deletion or inhibition; and whether this potential 
mechanism might explain the failure of  Dkk1 inhibition/deletion to have robust bone building effects 
on the skeleton. Mice heterozygous for a LacZ reporter allele knocked into the Sost coding sequence 
(Sost+/LacZ mice) were injected with a single 25-mg/kg dose of  Dkk1 antibody. Two days later, the mice 
were sacrificed and the femurs dissected, cryosectioned, and stained for LacZ expression. Dkk1 protein 
neutralization resulted in a qualitative increase in Sost reporter activity in the bone tissue (Figure 2, 
A and B). Additional, quantitative gene expression experiments were performed using cortical bone 
lysates from WT mice treated with Dkk1 antibody; from mice with bone-selective deletion of  Dkk1; 
and from transgenic 2.3kbCol1a1-Dkk1 mice, which overexpress Dkk1 in bone tissue (Supplemental Fig-
ure 1). Bone-selective deletion of  Dkk1 and antibody-mediated neutralization of  Dkk1 protein pro-
duced a significant increase in Sost expression (Figure 2C). In summary, Dkk1 protein neutralization or 
genetic deletion from bone resulted in a compensatory increase in Sost expression, which might explain 
the inefficacy of  Dkk1 inhibition in improving bone properties.
Bone-selective deletion of  Dkk1 consistently and robustly improves bone mass when Sost is co-deleted from the same 
cell population. In light of  the compensatory upregulation of  Sost that occurs when Dkk1 is inhibited or 
mutated, we next tested whether Sost induction was responsible for the meager skeletal effects of  bone-se-
lective Dkk1 deletion. Our goal was to determine whether Dkk1 deletion from bone could have a more con-
sistent and robust effect on bone mass if  the compensatory increase in Sost expression were prevented. To 
this end, we generated compound mutant mice with floxed loss-of-function alleles for Dkk1, with or with-
out co-deletion of  Sost in the same cells (i.e., Sostfl/fl mice). The Sost conditional mice have a floxed condi-
tional by inversion (COIN) module targeted to the single intron of  Sost, which undergoes inversion upon 
Figure 1. Conditional deletion of Dkk1 from bone cells 
or antibody-induced systemic neutralization of Dkk1 
in WT mice has minor effects on the skeleton. (A and 
B) Longitudinal dual-energy x-ray absorptiometry–
derived (DXA–derived) measures of whole-body bone 
mineral content (BMC) in (A) female and (B) male mice 
carrying homozygous floxed loss-of-function alleles 
for Dkk1, with (+Cre) or without (–Cre) the 10kbDmp1-Cre 
transgene. (C and D) μCT-derived measurements of 
bone volume fraction in the distal femur secondary 
spongiosa (C) and representative 3D tomographic 
reconstructions of the distal and midshaft femur 
(images shown represent female mice) (D) from Dkk1fl/fl  
mice with or without the 10kbDmp1-Cre transgene. (E 
and F) Percent change (from before to after treatment) 
in DXA-derived whole-body BMC (E) and peripher-
al quantitative CT-derived total mineral content at 
the proximal tibia (F) in male and female WT mice 
treated for 6 weeks with Dkk1 neutralizing antibody 
(αDkk1-mAb) or vehicle control. *P < 0.05 compared 
with sex-matched control mice. For all experiments, 
n = 11–15 mice/group. Data in A and B were analyzed 
using repeated-measures ANOVA followed by Fisher’s 
protected LSD post hoc tests. Data in C, E, and F were 
analyzed using 1-way ANOVA followed by Fisher’s 
protected LSD post hoc tests.
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Cre-mediated recombination (43). Again, we used the 10kbDmp1-Cre driver strain to induce recombination, 
and we included Cre-negative controls for all Sost/Dkk1 genotypes studied. Mice were scanned periodical-
ly using DXA from 4 to 16 weeks of  age. Body weight was similar among sex-matched mice regardless of  
the presence of  Cre or Sost/Dkk1 alleles (Supplemental Figure 3), and no significant differences in DXA 
properties were detected among Cre-negative control Sost/Dkk1 genotypes (Figure 3, A, C, and E; and 
Supplemental Figure 4). Among Cre-positive female mice, BMC was not significantly different between 
Dkk1 mutants and WT controls, but Sost mutants exhibited a significant increase in BMC compared with 
both WT mice (13%–29% increase, P < 0.05) and Dkk1 mutants (10%–26% increase, P < 0.05; Figure 3, 
B, D, and F). Surprisingly, whereas Dkk1 deletion from bone had no effect on BMC in Sost-replete mice, 
Dkk1 deletion in mice that underwent co-deletion of  Sost in the same cells exhibited very large increases 
in whole-body BMC compared with both WT mice (24%–75% increase, P < 0.05) and Sost mutant mice 
(10%–36% increase, P < 0.05). Male mice showed similar genotype effects, with the exception of  the Dkk1 
mutants, which exhibited significantly elevated hindlimb BMC (Supplemental Figure 4).
μCT measurements collected from the spine and femur of  these mice (16 weeks of  age) revealed an 
even more striking HBM-generating effect of  Dkk1 deletion in the presence of  Sost co-deletion (Figure 4). 
Bone volume fraction in the fifth lumbar vertebral (L5) spongiosa was significantly increased in male and 
female Dkk1 mutant mice (increases of  7% and 12%, respectively; P < 0.05 for both) compared with WT 
mice (Figure 4, A–C and Supplemental Figure 5). Sost mutant mice exhibited 35% and 27% increases over 
WT controls in L5 trabecular bone volume fraction (BV/TV) among male and female mice, respectively (P 
< 0.05 for both). Dkk1 deletion in mice that underwent co-deletion of  Sost exhibited a very large increase 
in L5 BV/TV, reaching 70%–80% (P < 0.05) beyond that in WT mice and ~45% (P < 0.05) beyond that in 
Sost mutant mice. Similar effects were found for other μCT measurements from the distal femur cancellous 
envelope (Figure 4, D–F, and Supplemental Figure 5) and from the midshaft femur cortex (Figure 4, G–I, 
and Supplemental Figure 5). Three-point bending tests on femurs taken from these mice revealed that the 
improved cortical bone properties observed consistently in Sost but not Dkk1 mutants, and to a much greater 
extent in Dkk1/Sost mutants, translated into improved mechanical properties (Figure 5, A–C, and Supple-
mental Figure 6). Histomorphometric measurements of  fluorochrome-derived bone formation rates from 
the midshaft femur were consistent with μCT and biomechanics results, and revealed potent anabolic action 
of  Dkk1 deletion when Sost was co-deleted (Figure 5, D and E). To assess changes in the WNT/β-catenin 
pathway under the different genetic conditions, demineralized histological sections from the mice were pre-
pared and stained for active β-catenin (Supplemental Figure 7). Qualitatively, we found an increase in active 
β-catenin signaling in all 3 mutants compared with WT controls, though a particularly strong signal was 
Figure 2. Genetically disabling or pharmacologically inhibiting Dkk1 increases Sost expression. (A and B) Representative photomicrographs of β-galac-
tosidase–reacted frozen sections cut from the thigh of female mice heterozygous for a Sost-knockin reporter allele (Sost+/LacZ). Mice were given a single 
injection of vehicle (Veh; A) or Dkk1-neutralizing antibody (αDkk1-mAb; B) 2 days prior to sacrifice. Blue staining in the cortical bone (CB) indicates endog-
enous Sost promoter activity. Mu, muscle; Ma, marrow. (C) Quantitative PCR of Sost transcripts in femoral and tibial cortical bone from female mice with 
conditional (10kbDmp1-Cre–mediated) homozygous inactivation of Dkk1 (left), from WT mice treated with αDkk1-mAb (center), and from 2.3kbCol1a1-Dkk1 
mice overexpressing Dkk1 in bone tissue (Dkk1-TG; right). *P < 0.05 compared with corresponding controls. n = 4–7 mice/group. Data in C were analyzed 
using 1-way ANOVA followed by Fisher’s protected LSD post hoc tests.
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observed in the single Dkk1 mutant mice. In summary, Dkk1 deletion from bone cells had little to no effect 
on skeletal properties, but the same Dkk1 mutations had dramatic osteoanabolic effects when moved onto a 
bone-selective Sost mutant background. These results suggest that the inability of  Dkk1 deletion to consis-
tently and robustly improve skeletal properties is at least partially explained by a compensatory increase in 
Sost expression.
Dkk1-neutralizing antibody consistently and robustly improves bone mass and strength when administered to Sost–/– 
but not Sost+/+ mice. Having found that Dkk1 conditional loss-of-function alleles improved bone properties 
only when moved onto a bone-selective Sost mutant background, we next applied this concept to Dkk1 
antibody efficacy, to determine whether we could create a condition where the otherwise inefficacious Dkk1 
antibody (e.g., Figure 1, D–F) is significantly anabolic. To address this possibility experimentally, global 
Sost-knockout (Sost–/–) and WT (Sost+/+) female mice were generated, raised to 8 weeks of  age, and adminis-
tered a Dkk1 antibody treatment regimen (25 mg/kg s.c., twice a week for 8 weeks). Dkk1 antibody therapy 
increased DXA-derived whole-body BMC by 12% (P < 0.05) among WT mice, but the same therapy in 
Sost–/– mice produced a 63% (P < 0.05) increase in BMC (Figure 6A and Supplemental Figure 8). pQCT-de-
rived changes in proximal tibia BMC were not significantly affected by Dkk1 antibody in WT mice, but 
in Sost–/– mice, Dkk1 antibody increased BMC by 32% (P < 0.05; Figure 6B and Supplemental Figure 8). 
μCT properties of  the femur after 8 weeks of  antibody treatment revealed a small but significant increase in 
cancellous bone volume fraction at the distal femur among WT mice treated with Dkk1 antibody, compared 
with WT mice treated with vehicle (2% difference, P < 0.05). A much greater difference was observed among 
Sost–/– mice treated with Dkk1 antibody versus vehicle (47% increase, P < 0.05; Figure 6, C and D, and Sup-
plemental Figure 8). No effect of  Dkk1 antibody was found among WT mice for midshaft femur and parietal 
μCT properties, whole femur mechanical properties, or periosteal bone formation rates (Figure 6, E–I, and 
Supplemental Figure 8), but each of  these end points exhibited significant antibody-induced increases when 
Figure 3. Conditional deletion of Dkk1 from bone consistently increases 
bone mineral content when Sost is co-deleted in the same bone cell pop-
ulation. Serial in vivo DXA scans of WT (Dkk1+/+ Sost+/+), Dkk1-flox (Dkk1fl/fl 
Sost+/+), Sost-flox (Dkk1+/+ Sostfl/fl), and compound flox (Dkk1fl/fl Sostfl/fl) mice, 
collected every 2–3 weeks and analyzed for (A and B) whole-body BMC, (C and 
D) lumbar spine BMC, and (E and F) BMC of the right hindlimb distal to the 
acetabulum. Data in A, C, and E show data from Cre-negative mice only; data 
in B, D, and F show data from Cre-positive mice only. Results in all panels 
are based on data from female mice; corresponding data from male mice are 
provided in the supplemental material. *P < 0.05 compared with WT mice; 
†P < 0.05 compared with Dkk1fl/fl mice; ‡P < 0.05 compared with Sostfl/fl mice. 
For all curves, n = 6–14 mice/group. All panels were analyzed using repeat-
ed-measures ANOVA followed by Fisher’s protected LSD post hoc tests.
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Figure 4. Conditional deletion of Dkk1 from bone improves cancellous and cortical bone architecture dramatically when Sost is co-deleted in 
the same bone cell population. μCT-derived measurement of L5 vertebral body cancellous bone, distal femur metaphyseal cancellous bone, and 
mid-femur cortical bone from WT (Dkk1+/+ Sost+/+), Dkk1-flox (Dkk1fl/fl Sost+/+), Sost-flox (Dkk1+/+ Sostfl/fl), and compound flox (Dkk1fl/fl Sostfl/fl) mice, 
with (maroon bars) and without (red bars) the 10kbDmp1-Cre transgene. Quantitative differences in L5 trabecular bone volume fraction (BV/TV; A) and 
thickness (Tb.Th; C) can be appreciated from representative 3D tomographic reconstructions (C) of the central 30% of the vertebra from Cre-posi-
tive mice. Quantitative differences in distal femur trabecular (D) bone volume fraction and (F) thickness can be appreciated from (E) representative 
3D reconstructions of the caudal half of the distal femur (the ventral half was digitally removed) in Cre-positive mice. Quantitative differences in 
midshaft femur cortical bone area (Ct.B.Ar; G) and thickness (Ct.Th; H) can be appreciated from (I) representative 2D slices taken from the femur 
mid-diaphysis of Cre-positive mice. Results in all panels are based on data/images from female mice; corresponding data/images from male mice 
are provided in the supplemental material. *P < 0.05 compared with Cre-matched WT mice; †P < 0.05 compared with Cre-matched Dkk1fl/fl mice; ‡P 
< 0.05 compared with Cre-matched Sostfl/fl mice. For all panels, n = 6–14 mice/group. All data panels were analyzed using 1-way ANOVA followed by 
Fisher’s protected LSD post hoc tests.
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tested in Sost–/– mice. In summary, Dkk1 antibody is highly effective at increasing bone mass and anabolic 
action in the skeleton when sclerostin upregulation is prevented; failure to suppress sclerostin upregulation 
renders Dkk1 antibody therapy ineffective.
Co-administration of  antibodies against sclerostin and Dkk1 to WT mice generates a synergistic effect on bone proper-
ties that far exceeds additive effects. Our results to this point indicated that Dkk1 antibody is highly osteoanabolic 
if  Sost upregulation is prevented at the genomic level. To take those findings into a more translational setting, 
we investigated the potential of  pharmacologically inhibiting sclerostin action using neutralizing antibody 
to sclerostin (Sclr-mAb) during Dkk1 antibody administration. For these experiments, we used 8-week-old 
female WT C57BL/6 (B6) mice and treated them with sclerostin antibody, Dkk1 antibody, or both (simulta-
neously), each at 25 mg/kg s.c., twice a week for 8 weeks. Consistent with our previous experiments, Dkk1-
mAb treatment alone resulted in little to no improvement in bone properties (Figure 7, A–G, and Supplemen-
tal Figure 9), but Dkk1-mAb administration in the presence of  Sclr-mAb (combination treatment) improved 
whole-body BMC by 43% compared with Sclr-mAb alone (Figure 7A); improved distal femur bone volume 
fraction and trabecular thickness by 26% and 74%, respectively (Figure 7, B–D); and improved femoral corti-
cal thickness and ultimate force by 7% and 11%, respectively (Figure 7, E and F). The improvements in bone 
properties generated by combination therapy were driven by both increased anabolic action (Figure 7G) and a 
reduction in resorption (Supplemental Figure 9). No obvious side effects of  single or dual antibody treatments 
were observed (e.g., body weight or behavioral changes). In summary, Dkk1 antibody is potently anabolic 
Figure 5. Conditional deletion of Dkk1 from bone improves mechanical properties and increases anabolic action significantly when Sost is co-deleted 
in the same bone cell population. (A–C) Three-point monotonic bending tests to failure conducted on whole femurs from WT (Dkk1+/+ Sost+/+), Dkk1-
flox (Dkk1fl/fl Sost+/+), Sost-flox (Dkk1+/+ Sostfl/fl), and compound flox (Dkk1fl/fl Sostfl/fl) mice, with (maroon bars) and without (red bars) the 10kbDmp1-Cre 
transgene. (A) Representative force-displacement curves from tests conducted on Cre-positive mice reveal differences in mechanical properties among 
genotypes; quantification of (B) ultimate force (peak height of the curve) and (C) energy absorbed (area under the curve). (D) Midshaft femur histologic 
sections from fluorochrome-labeled Cre-positive mice, calculated from 4 to 14 weeks, reveal differences in bone formation rates, which can be appre-
ciated by noting the distance between each of the 4 unique labels injected intermittently during the experimental period (calcein [green] at 4 weeks; 
oxytetracycline [yellow] at 6 weeks; demeclocycline [orange] at 8 weeks; alizarin [red] at 14 weeks). Panels on the right are magnifications of the indicat-
ed regions in the left panels. Width of white inset boxes, 350 μm. (E) Quantification of anabolic action on the periosteal surface (Ps), calculated as the 
bone formation rate per unit bone surface (BFR/BS). Results in all panels are based on data/images from female mice; corresponding data/images from 
male mice are provided in the supplemental material. For A–C, n = 6–14 mice/group. For E, n = 6–9 mice/group. *P < 0.05 compared with Cre-matched 
WT mice; †P < 0.05 compared with Cre-matched Dkk1fl/fl mice; ‡P < 0.05 compared with Cre-matched Sostfl/fl mice. Data in B, C, and E were analyzed using 
1-way ANOVA within each Cre grouping, followed by Fisher’s protected LSD post hoc tests.
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when sclerostin protein function is disabled by neutralizing antibody, supporting our previous observations 
that the skeletal efficacy of  Dkk1 inhibition can be unlocked if  the compensatory effects of  sclerostin upreg-
ulation are countered.
Discussion
Our main objective in the current communication was to understand why neutralization of  Dkk1 — a potent 
LRP5/6 antagonist — fails to generate a robust osteoanabolic response. We found that Dkk1 inhibition via 
Figure 6. Dkk1 neutralizing antibody has negligible skeletal effects in WT mice but has potent anabolic effects in Sost–/– mice. Percent change in (A) 
whole-body bone mineral content (BMC) and (B) proximal tibia BMC, calculated from just prior to the start of treatment (at 8 weeks of age) to sacrifice 
at 16 weeks of age, capturing 8 weeks of Dkk1 mAb (αDkk1-mAb) or vehicle injection in WT (red bars) and Sost–/– (purple bars) mice. (C–E) Femoral μCT 
properties in the distal metaphyseal spongiosa (bone volume fraction [BV/TV]) and midshaft cortex (cortical thickness [Ct.Th]) measured in 16-week-
old mice, after 8 weeks of vehicle or Dkk1 antibody treatment. Note the increase in bone mass induced by Dkk1 inhibition in Sost–/– but not WT mice. 
(G–I) Quantification of (G) ultimate force from 3-point bending tests of the femoral diaphysis and (I) bone formation rates from the same region, 
revealing increased bone strength and formation rates induced by Dkk1 inhibition in Sost–/– but not WT mice. Representative fluorochrome-labeled 
sections (H) illustrate the increase in bone formation over the experimental period (from yellow to red label). All panels are based on data/images from 
female mice. *P < 0.05 compared with genotype-matched vehicle-treated mice. For all experiments, n = 9–12 mice/group. Data in A, B, C, E, G, and I 
were analyzed using unpaired t tests within each Sost background.
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either selective genetic deletion in osteocytes, or antibody-based neutralization, resulted in increased Sost 
expression, as revealed by in vivo Sost reporter activity and quantitative PCR. To determine whether the 
increase in Sost was responsible for impaired anabolic action of  Dkk1 neutralization, we deleted Sost in 
osteocytes, deleted Sost globally, or neutralized sclerostin with antibody; in all 3 contexts, Dkk1 genetic dele-
tion from bone or pharmacologic Dkk1 inhibition was significantly and potently anabolic. In other words, 
the skeletal effects of  Dkk1 inhibition are strong but are only manifest when Sost/sclerostin is disabled. 
Those observations suggest that the increase in Sost/sclerostin that occurs under Dkk1-disabiling conditions 
acts to restrain the otherwise potently anabolic action of  Dkk1 inhibition. These data, in conjunction with 
those from other groups showing the reciprocal phenomenon (i.e., that Dkk1 expression is increased under 
Sost/sclerostin-disabling conditions [refs. 32–34]), indicate that sclerostin and Dkk1 might exhibit mutual 
compensatory regulation, where one molecule can become more highly expressed when the other is selec-
tively suppressed. Given that outcome, a larger question emerges: why does sclerostin neutralization result 
in such abundant increases in bone mass, despite the concurrent upregulation of  Dkk1, yet Dkk1 neutraliza-
tion is largely ineffective because of  the concurrent upregulation of  Sost?
One potential explanation for differences in sclerostin- versus Dkk1-mediated inhibition of  osteoanab-
olism might be related to selectivity of  local facilitator proteins. Recent work on the role of  LRP4 in bone 
indicates that the receptor serves as a facilitator of  sclerostin but not Dkk1 action on WNT1/β-catenin 
signaling (44). Although both sclerostin and Dkk1 interact with LRP4 (44, 45), neither overexpression nor 
knockdown of  LRP4 impacts Dkk1’s ability to impair WNT signaling in bone cells. Further, mice that 
express HBM-causing mutations in LRP5 (e.g., A214V or G171V) exhibit protection from bone-driven 
sclerostin overexpression but not Dkk1 overexpression (46, 47). Thus, while the biology of  sclerostin- and 
Figure 7. Dkk1-neutralizing antibody has potent osteoanabolic effects in WT mice when sclerostin is pharmacologically inhibited. (A) Percent change in 
whole-body bone mineral content (BMC) calculated from just prior to the start of treatment (at 8 weeks of age) to sacrifice at 16 weeks of age, capturing 
8 weeks of Dkk1 mAb (αDkk1-mAb; orange bars), sclerostin mAb (αSclr-mAb; yellow bars), co-injection with both antibodies (green bars), or vehicle (white 
bars) in female WT mice. Femoral μCT properties (B–E), biomechanical properties (F) and bone formation rates (G) were quantified for all treatment groups 
as described above. *P < 0.05 compared with vehicle-treated mice; †P < 0.05 compared with αDkk1-mAb-treated mice; ‡P < 0.05 compared with αSclr-
mAb–treated mice. For all panels, n = 10–12 mice/group. Data in all panels were analyzed using 1-way ANOVA, followed by Fisher’s protected LSD post hoc 
tests. BV/TV, trabecular bone volume fraction; Ct.Th, cortical thickness; Tb.Th, and thickness; BFR/BS, bone formation rate per unit bone surface.
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Dkk1-mediated effects on bone mass are not well understood, it is clear that these two molecules engage 
different mechanisms to affect WNT signaling and bone mass.
Previous genetic models of Dkk1 loss of function have relied on global heterozygous inactivation of the 
gene (+/–) or on naturally occurring global hypomorphic alleles (e.g., doubleridge) to assess skeletal conse-
quences of Dkk1 genetic impairment (29). Our experiments are the first to our knowledge to selectively target 
Dkk1 in bone tissue, using mice with homozygous Dkk1 floxed alleles that were recombined using the 10kbD-
mp1-Cre transgene. Those mice have a very mild skeletal phenotype, as most skeletal end points collected indi-
cate either no difference from Cre-negative mice or, if  differences were detected, the effect size was small. One 
potential explanation for the meager effect on phenotype could be the choice of Cre driver. Dkk1 expression 
has been detected in tissues other than bone (e.g., skin, bladder, prostate), so our approach which selectively 
inactivated Dkk1 in Dmp1-expressing cells could have “missed” a more relevant cell type capable of producing 
a stronger phenotype (e.g., early osteoblasts). However, three observations are noteworthy regarding our choice 
to use Dmp1-Cre for these experiments: (i) a body-wide screen of Dkk1 expression in young adult mice found 
that Dkk1 expression was restricted largely to bone (i.e., osteocytes), where very strong expression was detected 
(48); (ii) both fluorescence-activated cell sorting (49) and laser capture microdissection (50) approaches revealed 
that Dkk1 is highly upregulated in the osteocyte compared with the osteoblast; and (iii) our data indicate that 
Dkk1 deletion from Dmp1-expressing cells is highly anabolic if  Sost is inhibited, suggesting that inhibiting 
Dkk1 in this cell type can generate major effects if  the right conditions (e.g., Sost inhibition) are achieved. If  
the osteoanabolic Dkk1 inhibition alone were demonstrable, the mouse would likely be the most robust model 
to detect the effect given that mice have 10–20 times more circulating Dkk1, and 2–5 times less circulating 
sclerostin, than rats, cynomolgus monkeys, or humans (Monica Florio, Amgen Inc., personal communication).
It has also been noted that Dkk1 expression is more abundant in bone from young mice, and decreases 
dramatically in adolescent and adult mice, which might explain why Dkk1 antibody is more efficacious in 
young versus old mice (i.e., there is more target available to inhibit). However, mice in our Dmp1-Cre × 
Dkk1fl/fl experiments had Dkk1 deleted from bone since conception, and therefore effects should be mani-
fest in young mice, when Dkk1 is more highly expressed and potentially more active. Moreover, inspection 
of  DXA data at 4 weeks of  age and beyond into adulthood (effects during growth should be cumulative) 
revealed no changes in BMC. Another potential explanation for differences in sclerostin- versus Dkk1-me-
diated inhibition might be related to selectivity of  facilitator proteins. Recent work on the role of  LRP4 in 
bone indicates that the receptor serves as a facilitator of  sclerostin but not Dkk1 action on LRP5/6.
Despite its modest effect on bone gain in unperturbed, intact mice, Dkk1 antibody has proven effica-
cious in certain pathological contexts, such as fracture healing (30, 51), multiple myeloma (52, 53), and 
inflammatory arthritis (54, 55). Our data suggest that Dkk1 inhibition is highly anabolic in a healthy, 
intact adult mouse, if  the compensatory mechanisms are disabled. The Amgen group approached the 
Dkk1-sclerostin compensatory regulation phenomenon from a different angle, by looking to make 
anti-sclerostin antibody more efficacious (33). They reported that Dkk1 levels were increased in scle-
rostin antibody–treated mice, which they surmised might be restraining a fuller anabolic potential of  
sclerostin inhibition. That observation prompted them to develop a bispecific antibody that targets both 
sclerostin and Dkk1, which shows synergistic osteoanabolic action similar to what they (33) and we 
report for the combined use of  individual antibodies to sclerostin and Dkk1. Importantly, the two stud-
ies are consistent in finding a synergistic effect of  compound sclerostin/Dkk1 inhibition that far exceeds 
any potential additive effects. The molecular mechanisms that control transcriptional compensation/
upregulation between Sost and Dkk1 are unknown. Sost transcription is regulated by a number of  
pathways and factors, including Osx (56), Bmps (57), Tgf-β (58), histone deacetylases (HDACs) (59), 
cAMP/PKA (60), and hypoxia (61), among others (reviewed in ref. 62). Dkk1 transcription is regulated 
by some of  these same mechanisms (63, 64), but the mechanisms that confer reciprocal maintenance of  
WNT inhibition remain to be elucidated.
In summary, the osteoanabolic effects of  Dkk1 inhibition can be unleashed when sclerostin upregu-
lation is prevented. The role of  other secreted inhibitors in the compensatory expression mechanism are 
unknown. Canonical WNT signaling antagonists such as WISE (65), sFRP4 (66), and NOTUM (67), are 
associated with skeletal phenotypes in mice when mutated either globally or selectively in bone cells, and 
sclerostin inhibition enhances a number of  these transcripts in mouse bone (68). Whether pharmacologic 
modulation of  these or other members of  the secreted WNT inhibitory milieu can improve or otherwise 
tailor the efficacy of  sclerostin and/or Dkk1 neutralizing therapy is not known.
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Methods
Mice. Development of  the conditional Dkk1-flox mouse model has been reported elsewhere (69). Brief-
ly, these mice harbor head-to-toe loxP sequences flanking exons 1 and 2 of  the endogenous Dkk1 gene. 
Development of  the conditional Sost-flox mouse model has been reported elsewhere (43). Briefly, these 
mice harbor a COIN module in the single Sost intron, flanked by mutant loxP sequences introduced in a 
head-to-head arrangement. Development of  the Sost-LacZ knockin reporter/null mouse model has been 
reported elsewhere (43). Briefly, these mice harbor a LacZ-neo cassette in place of  the endogenous Sost 
coding sequence. Development of  the 10kbDmp1-Cre transgenic mouse model has been reported elsewhere 
(70). Briefly, these mice harbor a transgene expressing Cre recombinase, driven by a 9.6-kb fragment of  
the mouse dentin matrix protein 1 (Dmp1) promoter. Development of  the 2.3kbCol1a1-Dkk1 transgenic 
mouse model has been reported elsewhere (48). Briefly, these mice harbor a transgene expressing a mouse 
Dkk1 cDNA, driven by a 3.2-kb fragment of  the rat collagen 1A1 promoter. All mouse colonies were on a 
mixed background of  B6 and 129/SvJ, ranging from 93.8% to 100% B6, depending on the colony. For all 
experiments, littermate controls were used to stabilize the effect of  genetic background within experiments.
Antibodies. Details of  the development of  Dkk1- and sclerostin-neutralizing antibodies have been 
reported elsewhere (16, 54). Briefly, the Dkk1 antibody is a neutralizing rat mAb raised against mouse 
Dkk1, and the sclerostin antibody, which neutralizes mouse sclerostin, is a version of  a mouse mAb in 
which the amino acid sequence has been modified for use in rats. Antibodies were injected into mice s.c. at 
25 mg/kg, twice per week. Vehicle treatment was the buffer in which the antibodies were made. Treatment 
duration is indicated in the figure legend for each experiment.
DXA. Collection of  serial DXA measurements on live mice are described and validated elsewhere (13). 
Briefly, isoflurane-anesthetized mice were scanned periodically on a PIXImus II (GE Lunar). BMC was 
measured from the scans for the whole body, lumbar spine (L3–L5), and right lower limb.
μCT. Formalin-fixed femurs, L5 vertebrae, and craniums were scanned, reconstructed, and analyzed 
as previously described (13, 71, 72) using either 13-μm resolution, 50-kV peak tube potential and 151-
ms integration time (femur and vertebra) or 20-μm resolution, 50-kV peak tube potential and 125-ms 
integration time (cranium). Standard parameters (73) related to cancellous and cortical bone architec-
ture were measured.
pQCT. Collection of  serial tibial pQCT measurements in live mice is described elsewhere (74). Briefly, a 
single slice through the proximal tibia and one through the midshaft tibia were collected on isoflurane-anes-
thetized mice using a Stratec x-ray microscope (Stratec Inc.) at 70-μm resolution. Slices were analyzed for 
BMC using Stratec software in peel mode 2.
Histology. Mice were given various combinations of  oxytetracycline HCl (80 mg/kg, s.c.), calcein (12 
mg/kg, i.p.), alizarin complexone (20 mg/kg, i.p.), and demeclocycline (40 mg/kg, i.p.) to label miner-
alizing bone, at the time points indicated for each experiment (see figure legends). After sacrifice, femurs 
were processed, and cut, for plastic-embedded histomorphometry as previously described (72). Briefly, the 
periosteal bone formation parameters mineralizing surface (MS/BS; %), mineral apposition rate (MAR; 
μm/d), and bone formation rate (BFR/BS; μm3/μm2/yr), were calculated using standard protocols (75). 
Frozen sections of  unfixed Sost-LacZ reporter mouse thighs were cut and reacted for β-galactosidase activ-
ity as previously described (65). Demineralized paraffin-embedded longitudinal thin sections cut through 
the proximal tibia were immunolabeled for active β-catenin and counterstained for DAPI as previously 
described (65).
Mechanical properties. Parameters related to whole bone strength were measured using 3-point bending 
tests as previously described (41). Briefly, each femur was loaded to failure in monotonic compression, 
during which force and displacement were collected every 0.01 seconds. From the force/displacement 
curves, ultimate force and energy to failure were calculated using standard equations (76).
Serum C-terminal telopeptide (CtX). Serum concentration of  the resorption marker CtX was measured by 
a commercially available ELISA (RatLaps; IDS Inc.) as previously described (13, 72). Briefly, blood sam-
ples were collected from the retromandibular vein, permitted to clot at room temperature for 30 minutes, 
spun at 5,000 g to separate the serum, and frozen at –80°. Thawed serum samples were assayed for CtX in 
triplicate according to the manufacturer’s instructions.
Gene expression via quantitative PCR. Snap-frozen femur and tibia diaphyses were pulverized in liquid N2 
and processed for total RNA isolation as previously described (77). Briefly, total RNA was reversed tran-
scribed into cDNA using random hexamers; measured; then reacted for Sost, Dkk1, and the housekeeping 
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gene Hprt1 using quantitative PCR–based Taqman Assay-on-Demand kits. The ΔΔCT method was used to 
calculate relative expression, which was normalized for each sample using Hprt1.
Bone matrix properties. Humerus midshaft samples were processed and measured for bone matrix com-
position as previously described (78). Briefly, fixed bone samples were embedded in resin, cut, mounted 
to plastic slides, polished, and measured using FTIRI at the National Synchrotron Light Source at the 
Brookhaven National Laboratory (U10B beamline). A total of  64 scans were collected and averaged for 
each spectra, which were subsequently processed using previously published spectral analysis methods (79).
Statistics. Statistical analyses were computed with JMP (version 4.0, SAS Institute Inc.). The radio-
graphic, histomorphometric, and biomechanical endpoints were analyzed using 1- or 2-way ANOVA, with 
genotype and/or antibody treatment as main effects. Time series data were analyzed with repeated-mea-
sures ANOVA. When at least one main effect was significant, interactions terms were calculated and tested 
for significance. Differences among groups were tested for significance with Fisher’s protected least signif-
icant difference (LSD) post hoc test. Statistical significance was taken at P < 0.05. Two-tailed distributions 
were used for all analyses. Data are presented as mean ± SEM.
Study approval. All mouse procedures were performed in accordance with the IACUC guidelines and 
approvals.
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